MolMed TK: Lists filed for BoD and Auditors and extended for minority lists
Presentation of the lists of candidates for the appointment of the Board of Directors and of the Board of Statutory Auditors.
- (1888PressRelease) April 03, 2013 - With reference to the Shareholders' Meeting of MolMed S.p.A. (MLM.MI), convened for 22 April 2013 on single call to decide, among other items, on the appointment of members of the Board of Directors and of the Board of Statutory Auditors, MolMed announces that Shareholders Fininvest S.p.A., Science Park Raf S.p.A. winding-up, Airain Lda, Delfin S. à r.l. and H-Equity S.r.l. - members of the shareholders' agreement entered into on 14 December 2007 as subsequently amended - who certified the ownership of 35,319% of the ordinary shares of the Company, submitted the following lists for the renewal of the corporate bodies.
Extended deadline for the submission by minority Shareholders of lists for the appointment of the Board of Statutory Auditors
On expiry of the deadline, no list for the appointment of the Board of Statutory Auditors was filed by minority Shareholders. Pursuant to Article 144-sexies, paragraph 5 of the Italian Issuers Regulation, the deadline for the submission of lists for said appointment by minority Shareholders - with the same procedures and documentation reported in the Notice published on 13 March 2013 on MolMed's website (http://www.molmed.com/node/2161) and in abridged (in Italian) on the daily newspaper Milano Finanza - is thus extended to 2 April 2013 at 6:00 P.M., and the minimum threshold necessary for the submission is reduced by half.
This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.
About MolMed
MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)
Source: MolMed
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam